Nitric oxide opposes glucose-induced hypertension by suppressing sympathetic activity

Christie R. Claxton, Michael W Brands

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We have reported that glucose infusion in L-NAME-treated rats increased arterial pressure more than the additive responses to glucose and L-NAME alone. This suggested that nitric oxide synthesis inhibition potentiated the hypertensive response to chronic glucose infusion, and the heart rate data suggested an important role for the sympathetic nervous system. This study tested the role of the sympathetic nervous system by infusing glucose for 7 days in 4 groups of rats: L-NAME (L), L-NAME plus α- and β-adrenergic receptor blockade (LB), vehicle, or vehicle plus adrenergic receptor blockade (blockers). Mean arterial pressure (MAP, 24 hours per day) increased significantly in both the vehicle and blockers groups, confirming our previous reports. Likewise, MAP increased significantly more during glucose infusion in the L rats, from 120±3 mm Hg to 158±4 mm Hg by day 7, which was >3 times the increase in the vehicle rats. Heart rate also increased significantly in the L rats, from 391±4 to 426±8 bpm, and that increase was prevented completely in the LB rats. However, although the increase in MAP in the LB rats was significantly less than in the L rats, the hypertension was not prevented completely. The explanation for that partial inhibition is not clear, but the overall effectiveness of adrenergic receptor blockade to attenuate the potentiated hypertensive and tachycardic responses to glucose infusion in the L-NAME-treated rats versus the normal rats suggests that nitric oxide may help protect against hypertension during glucose infusion through suppression of sympathetic activity.

Original languageEnglish (US)
Pages (from-to)274-278
Number of pages5
JournalHypertension
Volume41
Issue number2
DOIs
StatePublished - Feb 1 2003

Fingerprint

Nitric Oxide
Hypertension
Glucose
NG-Nitroarginine Methyl Ester
Adrenergic Receptors
Sympathetic Nervous System
Arterial Pressure
Heart Rate

Keywords

  • Blood pressure
  • Glucose
  • Heart rate
  • Nitric oxide
  • Sympathetic nervous system

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Nitric oxide opposes glucose-induced hypertension by suppressing sympathetic activity. / Claxton, Christie R.; Brands, Michael W.

In: Hypertension, Vol. 41, No. 2, 01.02.2003, p. 274-278.

Research output: Contribution to journalArticle

@article{fc0211576c0c42a383e112964bba7921,
title = "Nitric oxide opposes glucose-induced hypertension by suppressing sympathetic activity",
abstract = "We have reported that glucose infusion in L-NAME-treated rats increased arterial pressure more than the additive responses to glucose and L-NAME alone. This suggested that nitric oxide synthesis inhibition potentiated the hypertensive response to chronic glucose infusion, and the heart rate data suggested an important role for the sympathetic nervous system. This study tested the role of the sympathetic nervous system by infusing glucose for 7 days in 4 groups of rats: L-NAME (L), L-NAME plus α- and β-adrenergic receptor blockade (LB), vehicle, or vehicle plus adrenergic receptor blockade (blockers). Mean arterial pressure (MAP, 24 hours per day) increased significantly in both the vehicle and blockers groups, confirming our previous reports. Likewise, MAP increased significantly more during glucose infusion in the L rats, from 120±3 mm Hg to 158±4 mm Hg by day 7, which was >3 times the increase in the vehicle rats. Heart rate also increased significantly in the L rats, from 391±4 to 426±8 bpm, and that increase was prevented completely in the LB rats. However, although the increase in MAP in the LB rats was significantly less than in the L rats, the hypertension was not prevented completely. The explanation for that partial inhibition is not clear, but the overall effectiveness of adrenergic receptor blockade to attenuate the potentiated hypertensive and tachycardic responses to glucose infusion in the L-NAME-treated rats versus the normal rats suggests that nitric oxide may help protect against hypertension during glucose infusion through suppression of sympathetic activity.",
keywords = "Blood pressure, Glucose, Heart rate, Nitric oxide, Sympathetic nervous system",
author = "Claxton, {Christie R.} and Brands, {Michael W}",
year = "2003",
month = "2",
day = "1",
doi = "10.1161/01.HYP.0000049620.70909.2E",
language = "English (US)",
volume = "41",
pages = "274--278",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Nitric oxide opposes glucose-induced hypertension by suppressing sympathetic activity

AU - Claxton, Christie R.

AU - Brands, Michael W

PY - 2003/2/1

Y1 - 2003/2/1

N2 - We have reported that glucose infusion in L-NAME-treated rats increased arterial pressure more than the additive responses to glucose and L-NAME alone. This suggested that nitric oxide synthesis inhibition potentiated the hypertensive response to chronic glucose infusion, and the heart rate data suggested an important role for the sympathetic nervous system. This study tested the role of the sympathetic nervous system by infusing glucose for 7 days in 4 groups of rats: L-NAME (L), L-NAME plus α- and β-adrenergic receptor blockade (LB), vehicle, or vehicle plus adrenergic receptor blockade (blockers). Mean arterial pressure (MAP, 24 hours per day) increased significantly in both the vehicle and blockers groups, confirming our previous reports. Likewise, MAP increased significantly more during glucose infusion in the L rats, from 120±3 mm Hg to 158±4 mm Hg by day 7, which was >3 times the increase in the vehicle rats. Heart rate also increased significantly in the L rats, from 391±4 to 426±8 bpm, and that increase was prevented completely in the LB rats. However, although the increase in MAP in the LB rats was significantly less than in the L rats, the hypertension was not prevented completely. The explanation for that partial inhibition is not clear, but the overall effectiveness of adrenergic receptor blockade to attenuate the potentiated hypertensive and tachycardic responses to glucose infusion in the L-NAME-treated rats versus the normal rats suggests that nitric oxide may help protect against hypertension during glucose infusion through suppression of sympathetic activity.

AB - We have reported that glucose infusion in L-NAME-treated rats increased arterial pressure more than the additive responses to glucose and L-NAME alone. This suggested that nitric oxide synthesis inhibition potentiated the hypertensive response to chronic glucose infusion, and the heart rate data suggested an important role for the sympathetic nervous system. This study tested the role of the sympathetic nervous system by infusing glucose for 7 days in 4 groups of rats: L-NAME (L), L-NAME plus α- and β-adrenergic receptor blockade (LB), vehicle, or vehicle plus adrenergic receptor blockade (blockers). Mean arterial pressure (MAP, 24 hours per day) increased significantly in both the vehicle and blockers groups, confirming our previous reports. Likewise, MAP increased significantly more during glucose infusion in the L rats, from 120±3 mm Hg to 158±4 mm Hg by day 7, which was >3 times the increase in the vehicle rats. Heart rate also increased significantly in the L rats, from 391±4 to 426±8 bpm, and that increase was prevented completely in the LB rats. However, although the increase in MAP in the LB rats was significantly less than in the L rats, the hypertension was not prevented completely. The explanation for that partial inhibition is not clear, but the overall effectiveness of adrenergic receptor blockade to attenuate the potentiated hypertensive and tachycardic responses to glucose infusion in the L-NAME-treated rats versus the normal rats suggests that nitric oxide may help protect against hypertension during glucose infusion through suppression of sympathetic activity.

KW - Blood pressure

KW - Glucose

KW - Heart rate

KW - Nitric oxide

KW - Sympathetic nervous system

UR - http://www.scopus.com/inward/record.url?scp=0037313249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037313249&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.0000049620.70909.2E

DO - 10.1161/01.HYP.0000049620.70909.2E

M3 - Article

C2 - 12574094

AN - SCOPUS:0037313249

VL - 41

SP - 274

EP - 278

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 2

ER -